Related Experiment Video
Updated: Mar 25, 2026
A Murine Model of Myocardial Ischemia-reperfusion Injury through Ligation of the Left Anterior Descending Artery
Published on: April 10, 2014
Effect of dexmedetomidine on myocardial ischemia-reperfusion injury
Shoulin Chen1, Fuzhou Hua1, Jun Lu1
1Department of Anesthesiology, The Second Affiliated Hospital, Nanchang University Nanchang 330006, Jiangxi, China.
Insights
Dexmedetomidine (Dex) reduces inflammation and protects the heart during coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB). It attenuated pro-inflammatory cytokines and promoted anti-inflammatory ones, while also reducing cardiac injury markers.
Area of Science:
- Anesthesiology and Critical Care Medicine
- Cardiovascular Surgery
- Immunology
Background:
- Cardiopulmonary bypass (CPB) triggers a significant systemic inflammatory response.
- The role of dexmedetomidine (Dex) in mitigating this inflammation during coronary artery bypass graft (CABG) surgery remains incompletely understood.
Purpose of the Study:
- To investigate the anti-inflammatory and myocardial protective effects of dexmedetomidine (Dex) in patients undergoing CABG surgery with CPB.
Main Methods:
- Dexmedetomidine was administered as a loading dose followed by continuous infusion during CABG with CPB.
- Serum levels of inflammatory cytokines (TNF-alpha, IL-6, IL-8, IL-10) were measured.
- Cardiac injury markers, including troponin-I (cTnI) and creatine kinase (CK-MB), were assessed.
Main Results:
- Dexmedetomidine administration inhibited the rise in cardiac injury markers (cTnI and CK-MB).
- Dexmedetomidine attenuated the production of pro-inflammatory cytokines: tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-8 (IL-8).
- Dexmedetomidine promoted the production of the anti-inflammatory cytokine interleukin-10 (IL-10).
Conclusions:
- Dexmedetomidine demonstrates significant anti-inflammatory properties during CABG with CPB.
- Dexmedetomidine provides myocardial protection by reducing cardiac injury markers.
- Dexmedetomidine effectively modulates the inflammatory response and offers cardioprotection in this surgical setting.
Abstract:
Cardiopulmonary bypass (CPB) is associated with a marked systemic inflammatory response. Although dexmedetomidine (Dex) is routinely used in cardiac surgery, the effect in reducing the inflammatory response in coronary artery bypass graft surgery (CABG) with CPB remains unclear. In this study, Dex was administered at a loading dose of 0.5 μg/kg for 10 min, followed by a continuous infusion of 0.5 μg/kg per hour until the completion of CABG with CPB. The levels of inflammatory cytokines in the serum, including tumor necrosis factor-alpha (TNFalpha), interleukin (IL)-6, IL-8 and IL-10, were measured to explore the inflammatory regulating function of Dex. In addition, troponin-I (cTnI) and creatine kinase (CK-MB) levels were studied to explore the myocardial protection provided by Dex. In this study, we showed Dex inhibited the increase in cTnI and CK-MB, attenuated the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-8, and promoted anti-inflammatory cytokine IL-10 production. These findings demonstrate that Dex regulates anti-inflammatory as well as myocardial protection potential in CABG with CPB.
